These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 22950794)

  • 21. MicroRNAs and type 2 diabetes mellitus: Molecular mechanisms and the effect of antidiabetic drug treatment.
    Yaribeygi H; Katsiki N; Behnam B; Iranpanah H; Sahebkar A
    Metabolism; 2018 Oct; 87():48-55. PubMed ID: 30253864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What causes the insulin resistance underlying obesity?
    Hardy OT; Czech MP; Corvera S
    Curr Opin Endocrinol Diabetes Obes; 2012 Apr; 19(2):81-7. PubMed ID: 22327367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of microRNAs in regulation of insulin secretion and insulin signaling involved in type 2 diabetes mellitus.
    Mendonca A; Thandapani P; Nagarajan PS; Venkatesh S; Sundaresan S
    J Biosci; 2022; 47():. PubMed ID: 36222140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adipose-derived exosomes: A novel adipokine in obesity-associated diabetes.
    Zhang B; Yang Y; Xiang L; Zhao Z; Ye R
    J Cell Physiol; 2019 Aug; 234(10):16692-16702. PubMed ID: 30807657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes.
    Kim G; Jo K; Kim KJ; Lee YH; Han E; Yoon HJ; Wang HJ; Kang ES; Yun M
    Cardiovasc Diabetol; 2015 Nov; 14():148. PubMed ID: 26538247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abdominal adiposity distribution in diabetic/prediabetic and nondiabetic populations: a meta-analysis.
    Lee JJ; Beretvas SN; Freeland-Graves JH
    J Obes; 2014; 2014():697264. PubMed ID: 25525511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs and other non-coding RNAs in adipose tissue and obesity: emerging roles as biomarkers and therapeutic targets.
    Lorente-Cebrián S; González-Muniesa P; Milagro FI; Martínez JA
    Clin Sci (Lond); 2019 Jan; 133(1):23-40. PubMed ID: 30606812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications.
    Ashoori MR; Rahmati-Yamchi M; Ostadrahimi A; Fekri Aval S; Zarghami N
    Biomed Pharmacother; 2017 Sep; 93():1326-1336. PubMed ID: 28747014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNAs in type 2 diabetes mellitus: potential role of physical exercise.
    Improta-Caria AC; De Sousa RAL; Roever L; Fernandes T; Oliveira EM; Aras Júnior R; Souza BSF
    Rev Cardiovasc Med; 2022 Jan; 23(1):29. PubMed ID: 35092221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoimmune aspects of type 2 diabetes mellitus - a mini-review.
    Itariu BK; Stulnig TM
    Gerontology; 2014; 60(3):189-96. PubMed ID: 24457898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of MicroRNAs in Type 2 Diabetes and Associated Vascular Complications.
    Banerjee J; Nema V; Dhas Y; Mishra N
    Biochimie; 2017 Aug; 139():9-19. PubMed ID: 28487136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis.
    Perseghin G
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S367-70. PubMed ID: 21525484
    [No Abstract]   [Full Text] [Related]  

  • 33. MicroRNA regulatory networks in human adipose tissue and obesity.
    Arner P; Kulyté A
    Nat Rev Endocrinol; 2015 May; 11(5):276-88. PubMed ID: 25732520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Emerging Role of MitomiRs in the Pathophysiology of Human Disease.
    Duarte FV; Palmeira CM; Rolo AP
    Adv Exp Med Biol; 2015; 888():123-54. PubMed ID: 26663182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.
    Szydełko J; Matyjaszek-Matuszek B
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of MicroRNAs in NAFLD/NASH.
    Szabo G; Csak T
    Dig Dis Sci; 2016 May; 61(5):1314-24. PubMed ID: 26769057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of caveolin-1 in human adipose tissue is upregulated in obesity and obesity-associated type 2 diabetes mellitus and related to inflammation.
    Catalán V; Gómez-Ambrosi J; Rodríguez A; Silva C; Rotellar F; Gil MJ; Cienfuegos JA; Salvador J; Frühbeck G
    Clin Endocrinol (Oxf); 2008 Feb; 68(2):213-9. PubMed ID: 17803693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are extracellular microRNAs involved in type 2 diabetes and related pathologies?
    Rome S
    Clin Biochem; 2013 Jul; 46(10-11):937-45. PubMed ID: 23499584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Micro-RNA Implications in Type-1 Diabetes Mellitus: A Review of Literature.
    Margaritis K; Margioula-Siarkou G; Giza S; Kotanidou EP; Tsinopoulou VR; Christoforidis A; Galli-Tsinopoulou A
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.